High affinity capture and concentration of quinacrine in polymorphonuclear neutrophils via vacuolar ATPase-mediated ion trapping: Comparison with other peripheral blood leukocytes and implications for the distribution of cationic drugs

Toxicology and Applied Pharmacology

Volumn 270, Issue 2, 2013, Pages 77-86

  Roy, Caroline ^a   Gagné, Valérie ^a   Fernandes, Maria J G ^a   Marceau, François ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Ion trapping; Lymphocytes; Macroautophagy; Polymorphonuclear leukocytes; Quinacrine; Vacuolar ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BAFILOMYCIN A1; MEPACRINE;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG RELEASE; DRUG TRANSPORT; HUMAN; HUMAN CELL; ION TRANSPORT; ION TRAPPING; LEUKOCYTE; LYMPHOCYTE; MONOCYTE; NEUTROPHIL; PHARMACOLOGICAL BLOCKING; PINOCYTOSIS;

AUTOPHAGY; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; KINETICS; LEUKOCYTES; MACROLIDES; MICROSCOPY, FLUORESCENCE; NEUTROPHILS; PINOCYTOSIS; QUINACRINE; REGRESSION ANALYSIS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84878178282     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.004     Document Type: Article

References (37)

1. Adams P.C., Sloan P., Morley A.R., Holt D.W. Peripheral neutrophil inclusions in amiodarone treated patients. Br. J. Clin. Pharmacol. 1986, 22:736-738.
2. Ammoury A., Michaud S., Paul C., Prost-Squarcioni C., Alvarez F., Lamant L., Launay F., Bazex J., Chouini-Lalanne N., Marguery M.C. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch. Dermatol. 2008, 144:92-96.
3. Baritussio A., Marzini S., Agostini M., Alberti A., Cimenti C., Bruttomesso D., Manzato E., Quaglino D., Pettanazo A. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L1189-L1199.
4. Bawolak M.T., Morissette G., Marceau F. Vacuolar ATPase-mediated sequestration of local anesthetics in swollen macroautophagosomes. Can. J. Anesth. 2010, 57:230-239.
5. Boya P., González-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., Métivier D., Meley D., Souquere S., Yoshimori T., Pierron G., Codogno P., Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005, 25:1025-1040.
6. Ciarimboli G. Organic cation transporters. Xenobiotica 2008, 38:936-971.
7. De Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 1974, 23:2495-2531.
8. Delage C., Lagacé R., Huart J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can. Med. Assoc. J. 1975, 112:1205-1208.
9. Diwu Z., Chen C.-S., Zhang C., Klaubert D.H., Haugland R.P. A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Chem. Biol. 1999, 6:411-418.
10. Dohgu S., Yamauchi A., Takata F., Sawada Y., Higuchi S., Naito M., Tsuruo T., Shirabe S., Niwa M., Katamine S., Kataoka Y. Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell. Mol. Neurobiol. 2004, 24:205-217.
11. Ehsanian R., Van Waes C., Feller S.M. Beyond DANN binding - a review of the potential mechanism mediating quinacrine's therapeutic activities in parasitic infections, inflammation and cancers. Cell Commun. Signal. 2011, 9:13.
12. Engler J.R., Zannettino A.C.W., Bailey C.G., Rasko J.E.J., Hughes T.P., White D.L. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 2011, 96:213-220.
13. Ertmer A., Huber V., Gilch S., Yoshimori T., Erfle V., Duyster J., Elsässer H.P., Schätzl H.M. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007, 21:936-942.
14. Fernandes M.J., Rollet-Labelle E., Paré G., Marois S., Tremblay M.L., Teillaud J.L., Naccache P.H. CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem. J. 2006, 393:351-359.
15. Földes-Filep É., Filep J.G. Mepacrine inhibits fMLP-induced activation of human neutrophil granulocytes, leukotriene B4 formation and fMLP binding. J. Leukoc. Biol. 1992, 52:545-550.
16. Gasparian A.V., Burkhart C.A., Purmal A.A., Brodsky L., Pal M., Saranadasa M., Bosykh D.A., Commane M., Guryanova O.A., Pal S., Safina A., Sviridov S., Koman I.E., Veith J., Komar A.A., Gudkov A.V., Gurova K.V. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci. Transl. Med. 2011, 3:95ra74.
17. Gupta A., Roy S., Lazar A.J.F., Wang W.L., McAuliffe J.C., Reynoso D., McMahon J., Taguchi T., Floris G., Debiec-Rychter M., Schöffski P., Trent J.A., Debnath J., Rubin B.P. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14333-14338.
18. Hayer-Zillgen M., Brüss M., Bönisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 2002, 136:829-836.
19. Kaufmann A.M., Krise J.P. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J. Pharm. Sci. 2007, 96:729-746.
20. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-Glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83:2451-2458.
21. Lee J.H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., Wolfe D.M., Martinez-Vicente M., Massey A.C., Sovak G., Uchiyama Y., Westaway D., Cuervo A.M., Nixon R.A. Lysosomal proteolysis and autophagy require presinilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010, 141:1146-1158.
22. Marceau F., Bawolak M.T., Bouthillier J., Morissette G. Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: a model for the distribution of lipophilic cationic drugs to autophagic vacuoles. Drug Metab. Dispos. 2009, 37:2271-2274.
23. Marceau F., Bawolak M.T., Lodge R., Bouthillier J., Gagné-Henley A., C.-Gaudreault R., Morissette G. Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs. Toxicol. Appl. Pharmacol. 2012, 259:1-12.
24. Marceau F., Roy C., Bouthillier J. Assessment of cation trapping by cellular acidic compartments. Endosomal Signaling - Methods in Enzymology 2013, (In press). P.M. Conn (Ed.).
25. Marois L., Vaillancourt M., Paré G., Gagné V., Fernandes M.J., Rollet-Labelle E., Naccache P.H. CIN85 modulates the down-regulation of FcγRIIa expression and function by c-Cbl in a PKC-dependent manner in human neutrophils. J. Biol. Chem. 2011, 286:15073-81504.
26. Morissette G., Moreau E., C.-Gaudreault R., Marceau F. N-substituted 4-aminobenzamides (procainamide analogs): an assessment of multiple cellular effects concerning ion trapping. Mol. Pharmacol. 2005, 68:1576-1589.
27. Morissette G., Lodge R., Marceau F. Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: procainamide-induced autophagic cell vacuolization. Toxicol. Appl. Pharmacol. 2008, 228:364-377.
28. Morissette G., Ammoury A., Rusu D., Marguery M., Lodge R., Poubelle P., Marceau F. Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br. J. Pharmacol. 2009, 157:1531-1540.
29. Namiuchi S., Kumagai S., Imura H., Suginoshita T., Hattori T., Hirata F. Quinacrine inhibits the primary but not the secondary proliferative response of human cytotoxic T cells to allogeneic non-T cell antigens. J. Immunol. 1984, 132:1456-1461.
30. +-ATPases. J. Biol. Chem. 1996, 271:15963-15970.
31. Pataki G., Czopf L., Jilling T., Marczin N., Catravas J., Matalon S. Regulation of fluid-phase endocytosis in alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 1995, 269:L520-L526.
32. Piccoli E., Nadai M., Mucignat Caretta C., Bergonzini V., Del Vecchio C., Ha H.R., Bigler L., Dal Zoppo D., Faggin E., Pettenazzo A., Orlando R., Salata C., Calistri A., Palu G., Baritussio A. Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype. Biochem. Pharmacol. 2011, 82:1234-1249.
33. Somani P., Simon V.A., Temesy-Armos P.N., Gross S.A., Didio L.J. Amiodarone-associated changes in human neutrophils. Am. J. Cardiol. 1986, 57:666-672.
34. Stadler K., Ha H.R., Ciminale V., Spirli C., Saletti G., Schiavon M., Bruttomesso D., Bigler L., Follath F., Pettenazzo A., Baritussio A. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am. J. Respir. Cell Mol. Biol. 2008, 39:142-149.
35. Vassallo P., Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007, 298:1312-1322.
36. Wyss P.A., Moor M.J., Bickel M.H. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J. Pharmacol. Exp. Ther. 1990, 254:502-507.
37. Zheng N., Zhang X., Rosania G.R. Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine. J. Pharmacol. Exp. Ther. 2011, 336:661-671.